DOCSLIB.ORG

(12)UK Patent Application (1S1GB ,„>2577037 ,,3,A 2577037

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12)UK Patent Application (1S1GB ,„>2577037 ,,3,A 2577037 (12)UK Patent Application (1S1GB ,„>2577037 ,,3,A (43) Date of A Publication 18.03.2020 (21) Application No: 1812997.3 (51) INT CL: C12N 15/52 (2006.01) C12P 33/02 (2006.01) (22) Date of Filing: 09.08.2018 C12R 1/32 (2006.01) C12R 1/365 (2006.01) (56) Documents Cited: GB 2102429 A EP 3112472 A (71) Applicant(s): WO 2001/031050 A US 4345029 A Cambrex Karlskoga AB US 4320195 A (Incorporated in Sweden) Appl Environ Microbiol, published online 4 May 2018, S-691 85 Karlskoga, Sweden Liu et al, "Characterization and engineering of 3- ketosteroid 9a-hydroxylases in Mycobacterium Rijksuniversiteit Groningen neoarum ATCC 25795 for the development of (Incorporated in the Netherlands) androst-1,4- diene3,17-dione and 9a-hydroxy- Broerstraat 5, 9712 CP Groningen, Netherlands androst-4-ene-3,17-dione-producing strains" Appl Environ Microbiol, Vol 77 (2011), Wilbrink et al, (72) Inventor(s): "FadD19 of Rhodococcus rhodochrous DMS43269, a Jonathan Knight steroid-coenzyme A ligase essential for degradation Cecilia Kvarnstrom Branneby of C-24 branched sterol side chains", pp 4455-4464 Lubbert Dijkhuizen FEMS Microbiol Letts, Vol 205 (2001), van der Geize et Janet Maria Petrusma al, "Unmarked gene deletion mutagenesis of kstD, Laura Fernandez De Las Heras encoding 3-ketosteroid deltal-dehydrogenase, in Rhodococcus erythropolis SQ1 using sacB as a counter-selectable marker", pp 197-202 (74) Agent and/or Address for Service: J Steroid Biochem Mol Biol, Vol 172 (2017), Guevara Potter Clarkson LLP et al, "Functional characterization of 3-ketosteroid 9a- The Belgrave Centre, Talbot Street, NOTTINGHAM, hydroxylases in Rhodococcus ruber strain chol-4", NG1 5GG, United Kingdom pp 176-187 J Bacteriol, Vol 194 (2012), Mohn et al, "Gene cluster encoding cholate catabolism in Rhodococcus spp." pp 6712-6719 Microb Cell Fact, Vol 17 (May 2018), Zhang et al, "Identification, function, and application of 3- ketosteroid delta 1-dehydrogenase isozymes in Mycobacterium neoaurum DSM 1381 for the production of steroidic synthons", pp 77 J Steroid Biochem Mol Biol, Vol 138 (2013), Bragin et al, "Comparative analysis of genes encoding key steroid core oxidation enzymes in fast-growing Mycobacterium spp. strains", pp 41-53 (58) Field of Search: INT CLC12N, C12P, C12R Other: EPODOC, WPI, Patent Fulltext, BIOSIS, MEDLINE (54) Title of the Invention: Genetically-modified bacteria and uses thereof Abstract Title: Bacteria modified in the steroid metabolism pathway GB (57) A genetically-modified bacterium, for example of the class Actinobacteria, and the use ofsuch a bacterium in the bioconversion of a steroidal substrate into a steroidal product of interest is disclosed. The bacterium is blocked in the steroid metabolism pathway prior to the degradation of the polycyclic ring system, and at the steroid side chain degradation pathway. In a preferred embodiment the genetic modification comprises inactivation of the genes 2577037 kshA1, kshA2, kshA3, kshA4 and kshA5. A The provisions of paragraph 6 and 7 of Schedule 1 to the Patents Rules 2007 have effect in respect of this application, restricting availability of samples of specified biological material to experts in accordance with those provisions. At least one drawing originally filed was informal and the print reproduced here is taken from a later filed formal copy. side chain, activation 4 3~oxo~9~hydroxy~4~cholenic acid 3-oxo-7,9-dihydroxy-4-choienic aci 29 01 20 GM est® ! (Pwe ί ( P io S fetad) or 7*H^t hcfeteral PIC 1 <R FJV3. 0 29 01 20 souepunqe 9Appy θ θ θ C:> CZ5 θ Ο ΟΟ CD <Ν 93uepunqv9Appy Qouepimqy θλι|Β|Θ^ eouepunqv 9λι|Β|θ^ 29 01 20 souBpunqyQAppy 10/21 ! Λ HU.Γ “ Ίϋ 11/21 29 01 20 FIG. 12 29 01 20 nw 29 01 20 eouepunqv θΛμθιθ^ 29 01 20 nw 3-oxo-7-hydroxy-4-cholenic acid co 20 01 29 CM CZ> O> OO i'-'— CO LO CO OsJ -y C^j nvni 20 81 OH 01 29 co lo o uo <o> lo cS lo o lo co cS co cS CO CO CO -^r CO CO CxJI CM ^-- 'c— ’ v™ nw 20 6l· ΌΗ 01 29 C2> LO cS UO O UO O LX'S kO cS UO O UO O co uo m co e*> c-si cn x— ! nvni 29 01 20 nw FIG. 20 CO O CO> O CO O O CO> O O CO O CZ> C21> C21") C2> ■^r c-si cz> CO CO Oxi CM nw 1 GENETICALLY-MODIFIED BACTERIA AND USES THEREOF The present invention relates to genetically-modified bacteria and the use of such bacteria in the bioconversion of steroidal substrates into steroidal compounds of interest. The 5 genetically-modified bacteria may be from the genera Rhodococcus or Mycobacterium. Steroids are a large and diverse class of organic compounds, with many essential functions in eukaryotic organisms. For example, naturally occurring steroids are involved in maintaining cell membrane fluidity, controlling functions of the male and female 10 reproductive systems and modulating inflammation. As signalling through steroid controlled pathways is important in a wide variety of processes, the ability to modulate these pathways using synthetically produced steroid drugs means they are an important class of pharmaceuticals. For example, corticosteroids 15 are used as anti-inflammatories for the treatment of conditions such as asthma and rheumatoid arthritis, synthetic steroid hormones are widely used as hormonal contraceptives and anabolic steroids can be used to increase muscle mass and athletic performance. 20 The synthesis of steroids for use as pharmaceuticals involves either semi-synthesis from natural sterol precursors or total synthesis from simpler organic molecules. Semi­ synthesis from sterol precursors such as cholesterol often involves the use of bacteria. The advantages of using bacteria to carry out these bioconversions are that the synthesis involves less steps and the reactions performed by the enzymes are 25 stereospecific, resulting in the production of the desired isomers without the need for protection and deprotection used in traditional chemical synthesis. The products of bacterial bioconversions can then be used as pharmaceuticals or as precursors for further chemical modification to produce the compound of interest. 30 Steroids naturally occur in both plant, animal and fungal species, and are produced by certain species of bacteria. Despite them only occurring naturally in only a few bacterial species, several bacterial species are able to metabolise sterol compounds as growth substrates. Examples of bacteria that can degrade sterol compounds include those from the genera Rhodococcus and Mycobacterium. 35 The bacterial sterol metabolism pathway involves progressive oxidation of the sterol side­ chain, and breakdown of the polycyclic ring system. The pathway of sterol side-chain 2 degradation in Rhodococcus has been previously investigated using mutant strains (Wilbrink et al, 2011. Applied and Environmental Microbiology, 77(13):4455-4464) and an overview of the cholesterol catabolic pathway is shown in Figure 1. It has now been found that bacterial species may be used for steroid compound production by genetic 5 modification to block the degradation pathway prior to breakdown of the polycyclic ring system and at various points in side-chain oxidation to allow accumulation of the steroidal compounds of interest in order to improve the yields obtained. In a first aspect, the invention provides a genetically-modified bacterium blocked in the 10 steroid metabolism pathway prior to degradation of the polycyclic steroid ring system, wherein the bacterium is disrupted in the steroid side-chain degradation pathway, and wherein the bacterium converts a steroidal substrate into a steroidal product of interest. By “steroid” or “steroidal” compounds we include the meaning of a class of natural or 15 synthetic organic compounds derived from the steroid core structure represented below (with lUPAC-approved ring lettering and atom numbering): 20 Steroidal compounds generally comprise four fused rings (three six-member cyclohexane rings (rings A, B and C above) and one five-member cyclopentane ring (ring D above)) but vary by the functional groups attached to that four-ring core and by the oxidation state of the rings. For example, sterols are a sub-group of steroidal compounds where one of the defining features is the presence of a hydroxy group (OH) at position 3 or the structure 25 shown above. The structure formed by the atoms labelled 20 to 27 (including positions 241 and 242) in the above diagram is referred to as the steroid side-chain. Non-limiting examples of steroids include: sterols, 3-oxo-4-cholenic acid, 3-oxo-chola-4,22-dien-24-oic acid, 3-oxo-7-hydroxy-4-cholenic acid, 3-oxo-9-hydroxy-4-cholenic acid, 3-oxo-7,9- dihydroxy-4-cholenic acid, 3-oxo-23,24-bisnor-4-cholene-22-oic acid (4-BNC), 3-oxo- 30 23,24-bisnor-1,4-choladiene-22-oic acid (1,4-BNC), 4-androstene-3,17-dione (AD), 1,4- androstadiene-3,17-dione (ADD), sex steroids (e.g. progesterone, testosterone, estradiol), 3 corticosteroids (e.g. cortisol), neurosteroids (e.g. DHEA and allopregnanolone), and secosteroids (e.g. ergocalciferol, cholecalciferol, and calcitriol). Non-limiting examples of steroidal compounds are also shown in Figure 4. 5 By “disrupted in the steroid side-chain degradation pathway” we include the meaning of a bacterium in which the normal degradation of the steroid side-chain is impaired. Normally, degradation of the steroid side-chain involves the initial cycle of side-chain activation followed by three successive cycles of β-oxidation (i.e. first, second, and third cycles of β- oxidation). In an unimpaired side-chain degradation pathway, the final product of the side­ 10 chain degradation steps is usually 4-androstene-3,17-dione (AD). Thus, a bacterium disrupted in the steroid side-chain degradation pathway will accumulate steroidal products that are upstream of the production of AD.
Load more

Recommended publications
  • ATP-Citrate Lyase Has an Essential Role in Cytosolic Acetyl-Coa Production in Arabidopsis Beth Leann Fatland Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2002 ATP-citrate lyase has an essential role in cytosolic acetyl-CoA production in Arabidopsis Beth LeAnn Fatland Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Molecular Biology Commons, and the Plant Sciences Commons Recommended Citation Fatland, Beth LeAnn, "ATP-citrate lyase has an essential role in cytosolic acetyl-CoA production in Arabidopsis " (2002). Retrospective Theses and Dissertations. 1218. https://lib.dr.iastate.edu/rtd/1218 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. ATP-citrate lyase has an essential role in cytosolic acetyl-CoA production in Arabidopsis by Beth LeAnn Fatland A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Plant Physiology Program of Study Committee: Eve Syrkin Wurtele (Major Professor) James Colbert Harry Homer Basil Nikolau Martin Spalding Iowa State University Ames, Iowa 2002 UMI Number: 3158393 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted.
    [Show full text]
  • Structural Basis for Human Sterol Isomerase in Cholesterol Biosynthesis and Multidrug Recognition
    ARTICLE https://doi.org/10.1038/s41467-019-10279-w OPEN Structural basis for human sterol isomerase in cholesterol biosynthesis and multidrug recognition Tao Long 1, Abdirahman Hassan 1, Bonne M Thompson2, Jeffrey G McDonald1,2, Jiawei Wang3 & Xiaochun Li 1,4 3-β-hydroxysteroid-Δ8, Δ7-isomerase, known as Emopamil-Binding Protein (EBP), is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis, autophagy, 1234567890():,; oligodendrocyte formation. The mutation on EBP can cause Conradi-Hunermann syndrome, an inborn error. Interestingly, EBP binds an abundance of structurally diverse pharmacolo- gically active compounds, causing drug resistance. Here, we report two crystal structures of human EBP, one in complex with the anti-breast cancer drug tamoxifen and the other in complex with the cholesterol biosynthesis inhibitor U18666A. EBP adopts an unreported fold involving five transmembrane-helices (TMs) that creates a membrane cavity presenting a pharmacological binding site that accommodates multiple different ligands. The compounds exploit their positively-charged amine group to mimic the carbocationic sterol intermediate. Mutagenesis studies on specific residues abolish the isomerase activity and decrease the multidrug binding capacity. This work reveals the catalytic mechanism of EBP-mediated isomerization in cholesterol biosynthesis and how this protein may act as a multi-drug binder. 1 Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2 Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 3 State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China. 4 Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,906,307 B2 S0e Et Al
    US007906307B2 (12) United States Patent (10) Patent No.: US 7,906,307 B2 S0e et al. (45) Date of Patent: Mar. 15, 2011 (54) VARIANT LIPIDACYLTRANSFERASES AND 4,683.202 A 7, 1987 Mullis METHODS OF MAKING 4,689,297 A 8, 1987 Good 4,707,291 A 11, 1987 Thom 4,707,364 A 11/1987 Barach (75) Inventors: Jorn Borch Soe, Tilst (DK); Jorn 4,708,876 A 1 1/1987 Yokoyama Dalgaard Mikkelson, Hvidovre (DK); 4,798,793 A 1/1989 Eigtved 4,808,417 A 2f1989 Masuda Arno de Kreij. Geneve (CH) 4,810,414 A 3/1989 Huge-Jensen 4,814,331 A 3, 1989 Kerkenaar (73) Assignee: Danisco A/S, Copenhagen (DK) 4,818,695 A 4/1989 Eigtved 4,826,767 A 5/1989 Hansen 4,865,866 A 9, 1989 Moore (*) Notice: Subject to any disclaimer, the term of this 4,904.483. A 2f1990 Christensen patent is extended or adjusted under 35 4,916,064 A 4, 1990 Derez U.S.C. 154(b) by 0 days. 5,112,624 A 5/1992 Johna 5,213,968 A 5, 1993 Castle 5,219,733 A 6/1993 Myojo (21) Appl. No.: 11/852,274 5,219,744 A 6/1993 Kurashige 5,232,846 A 8, 1993 Takeda (22) Filed: Sep. 7, 2007 5,264,367 A 11/1993 Aalrust (Continued) (65) Prior Publication Data US 2008/OO70287 A1 Mar. 20, 2008 FOREIGN PATENT DOCUMENTS AR 331094 2, 1995 Related U.S. Application Data (Continued) (63) Continuation-in-part of application No.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,642,021 B2 Brautigam Et Al
    USOO8642021B2 (12) United States Patent (10) Patent No.: US 8,642,021 B2 Brautigam et al. (45) Date of Patent: *Feb. 4, 2014 (54) CONDITIONING COMPOSITION FOR HAIR FOREIGN PATENT DOCUMENTS (75) Inventors: Ina Brautigam, Darmstadt (DE); Frank DE 2630560 1/1978 ............... A61K 7.48 EP O315541 5, 1989 ............... A61K 7.48 Hermes, Seeheim (DE) FR 241 1001 7, 1979 ............... A61K 700 JP O7327633. A * 12/1995 (73) Assignee: Kao Germany GmbH, Darmstadt (DE) WO WOOO28966 A1 * 5, 2000 WO WOO3,070208 A1 8/2003 ............. A61K 7,134 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 1520 days. Abstract Accession No. 2000:35.1345 from the CaPlus database on This patent is Subject to a terminal dis STN, the bibliography, abstract and indexing data for WO 200028966 claimer. A1, downloaded on Aug. 8, 2007, 2 pages.* Quest International: “Yogurtene” Cosmetic Ingredients (Jun. 2000) (21) Appl. No.: 11/001,840 pp. 1-17.* Machine translation of JP 07327633A dowloaded from the JPO Feb. (22) Filed: Dec. 2, 2004 14, 2012.* thehealthyeating.org website (www.healthyeating.org/Milk-Dairy/ (65) Prior Publication Data Nutrients-in-Milk-Cheese-Yogurt/Yogurt-Nutrition. aspx?Referer-dairycouncilofca (downloaded Feb. 28, 2013).* US 2005/O152863 A1 Jul. 14, 2005 Website: Clairol's Touch of Yoghurt Shampoo (http://brandfailures. (30) Foreign Application Priority Data blogspot.com/2006/12/other-famous-brand-idea-failures.html) downloaded Feb. 28, 2013).* Skin Deep website http://www.ewg.org/skindeepfingredient/ Dec. 5, 2003 (EP) ..................................... O3O27985 702759/GUAR HYDROXYPROPYLTRIMONIUM CHLO RIDE/downloaded Sep.
    [Show full text]
  • Neonatal Parenteral Nutrition [D3] Lipids
    National Institute for Health and Care Excellence Draft for consultation Neonatal parenteral nutrition [D3] Lipids NICE guideline tbc Evidence reviews September 2019 Draft for Consultation These evidence reviews were developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists DRAFT FOR CONSULTATION Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Zheng Zhao, Delft University of Technology Marcel A. van den Broek, Delft University of Technology S. Aljoscha Wahl, Delft University of Technology Wilbert H. Heijne, DSM Biotechnology Center Roel A. Bovenberg, DSM Biotechnology Center Joseph J. Heijnen, Delft University of Technology An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Marco A. van den Berg, DSM Biotechnology Center Peter J.T. Verheijen, Delft University of Technology Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. PchrCyc: Penicillium rubens Wisconsin 54-1255 Cellular Overview Connections between pathways are omitted for legibility. Liang Wu, DSM Biotechnology Center Walter M. van Gulik, Delft University of Technology L-quinate phosphate a sugar a sugar a sugar a sugar multidrug multidrug a dicarboxylate phosphate a proteinogenic 2+ 2+ + met met nicotinate Mg Mg a cation a cation K + L-fucose L-fucose L-quinate L-quinate L-quinate ammonium UDP ammonium ammonium H O pro met amino acid a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar K oxaloacetate L-carnitine L-carnitine L-carnitine 2 phosphate quinic acid brain-specific hypothetical hypothetical hypothetical hypothetical
    [Show full text]
  • WO 2016/209732 Al 29 December 2016 (29.12.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/209732 Al 29 December 2016 (29.12.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07H 1/00 (2006.01) A61K 31/05 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07J 41/00 (2006.01) A61K 47/26 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/US20 16/038 134 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 17 June 2016 (17.06.2016) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/183,400 23 June 2015 (23.06.2015) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 15/184,014 16 June 2016 (16.06.2016) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventor; and SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant : WU, Nian [US/US]; 103 Sassafras Court, GW, KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • A Study of the Function and Physiological Forms of Ergosterol in Saccharomyces Cerevisiae
    AN ABSTRACT OF THE THESIS OF BRUCE GORDON ADAMS for the Ph. D. (Name of student) (Degree) Microbiology April 25, 1968 in (Microbial Physiology) presented on (Major) (Date) Title: A STUDY OF THE FUNCTION AND PHYSIOLOGICAL FORMS OF ERGOSTEROL IN SACCHAROMYCES CEREVISIAE Abstract approved: A water - soluble complex containing ergosterol together with a component of yeast has been isolated. The complex can be iso- lated from commercial yeast extract to which ergosterol has been added or directly from whole yeast cells. The complexing agent from yeast extract is also capable of solubilizing cholesterol and a long chain hydrocarbon, hexadecane. The complexing agent has been shown to be a polysaccharide and appears to be composed solely of glucose subunits. The complexing agent does not appear to be glycogen. The binding between the sterol and the polysaccharide appears to be noncovalent. The complex is easily prepared and is stable in aqueous solution; ergosterol in this solution is meta- bolically available to yeast cells to which it is added. Data obtained from acid hydrolysis and extraction of yeast have demonstrated that routine saponification does not recover total sterol from the cells. This suggests the existence of a form of ergosterol resistant to saponification. Time course analyses of sterol synthesis by nonproliferating cell suspensions reveal an inverse relationship between the amounts of base labile and acid labile forms of sterol. These data give strong presumptive evi- dence for dual forms of ergosterol which are interconvertible according to the respiratory state of the cell. Experiments dealing with the effect of respiratory inhibitors on sterol synthesis in nonprofilerating cell suspensions suggest that the synthesis and physiological form of ergosterol is inti- mately related to the integrity of the respiratory apparatus and that the DNA encoding for the synthesis and regulation of ergo- sterol is located in the mitochondria.
    [Show full text]
  • The Free Sterol Content of Selected Clones of Alfalfa As Related to Seed Infestation by the Alfalfa Seed Chalcid
    Utah State University DigitalCommons@USU All Graduate Theses and Dissertations Graduate Studies 5-1967 The Free Sterol Content of Selected Clones of Alfalfa as Related to Seed Infestation by the Alfalfa Seed Chalcid Rex Alton Richards Utah State University Follow this and additional works at: https://digitalcommons.usu.edu/etd Part of the Plant Sciences Commons Recommended Citation Richards, Rex Alton, "The Free Sterol Content of Selected Clones of Alfalfa as Related to Seed Infestation by the Alfalfa Seed Chalcid" (1967). All Graduate Theses and Dissertations. 2974. https://digitalcommons.usu.edu/etd/2974 This Thesis is brought to you for free and open access by the Graduate Studies at DigitalCommons@USU. It has been accepted for inclusion in All Graduate Theses and Dissertations by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. THE FREE STEROL CONTENT OF SELECTED CLONES OF ALFALFA AS RELATED TO SEED INFESTATION BY THE ALFALFA SEED CHALCID by Rex Alton Ri chards A thesis submitted in partial fulfillment of the requirements f or the degree of MASTER OF SCIENCE in Plant Nutrition and Biochemistry UTAH STATE UNIVERSITY Logan , Utah 1967 ACKNOWLEDGMENTS I would like t o express my sincere appreciation t o my major professor, Dr . Keith R. Allred , and to Dr. Herman H. Wiebe and Dr. Orson S. Cannon of my thesis committee for their assistance and direction in this study. wish to acknowledge my parents, Mr . and Mrs. Alton F. Richards, for their aid and encouragement. Also, I wish to acknowledge the financial support given me through the William C.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,955,813 B2 De Kreijet Al
    US007955813B2 (12) United States Patent (10) Patent No.: US 7,955,813 B2 De Kreijet al. (45) Date of Patent: *Jun. 7, 2011 (54) METHOD OF USING LIPID 3,939,350 A 2f1976 Kronicket al. ACYLTRANSFERASE 3,973,042 A 8, 1976 Kosikowski 3.996,345 A 12/1976 Ullman et al. 4,034,124 A 7, 1977 Van Dam (75) Inventors: Arno De Kreij, Papendrecht (NL); 4,065,580 A 12/1977 Feldman Susan Mampusti Madrid, Vedbaek 4,160,848 A T. 1979 Vidal 4,202,941 A 5/1980 Terada (DK); Jorn Dalgaard Mikkelsen, 4,275,149 A 6/1981 Litman et al. Hvidovre (DK); Jorn Borch Soe, Tilst 4,277.437 A 7/1981 Maggio (DK) 4,366,241 A 12/1982 Tom et al. 4,399.218 A 8, 1983 Gauhl (73) Assignee: Danisco, A/S, Copenhagen (DK) 4,567.046 A 1/1986 Inoue 4,683.202 A 7, 1987 Mullis 4,689,297 A 8, 1987 Good (*) Notice: Subject to any disclaimer, the term of this 4,707,291 A 11, 1987 Thom patent is extended or adjusted under 35 4,707,364 A 11/1987 Barach U.S.C. 154(b) by 1056 days. 4,708,876 A 1 1/1987 Yokoyama 4,798,793 A 1/1989 Eigtved This patent is Subject to a terminal dis 4,808,417 A 2f1989 Masuda claimer. 4,810,414 A 3/1989 Huge-Jensen 4,814,331 A 3, 1989 Kerkenaar 4,816,567 A 3/1989 Cabilly et al. (21) Appl. No.: 11/483,345 4,818,695 A 4/1989 Eigtved 4,826,767 A 5/1989 Hansen (22) Filed: Jul.
    [Show full text]
  • Evidence Review D7
    National Institute for Health and Care Excellence Draft for consultation Neonatal parenteral nutrition [D7] Ratio of non-nitrogen energy to nitrogen NICE guideline tbc Evidence reviews September 2019 Draft for consultation These evidence reviews were developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists DRAFT FOR CONSULTATION Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]
  • Molecular Biogeochemistry, Lecture 4
    12.158 Lecture 4 • Steroids – Structures and biosynthesis – Diagenesis – Steroidal hydrocarbons; stereochemistry vs maturity – Steroids as age and environment indicators – Enigmatic steroids 2- and 3-alkyl and carboxysteroids Evolution of Hopane & Sterol Bioynthesis BHP Squalene Dippploptene o2 BACTERIA Squalene epoxide O o2 EUCARYA HO HO C24 substitution Lanosterol Cholesterol by algae some bacteria - Methylococcus Mycobacteria, Myxobacteria Algal Steroids •Encode a variety of age-diagnostic signatures – C-isotopes + steroids from algae & plants H chlorophyceans HO C29 diatoms H HO C28 chrysophytes C30 H HO dinoflagellates C30 H HO ‘bio’ ‘geo’ Functional Role of Sterols These images have been removed due to copyright restrictions. While it became clear very early that cholesterol plays an important role in controlling cell membrane permeability by reducing average fluidity, it appears now that it has a key role in the lateral organization of membranes and free volume distribution . These two parameters seem to be involved in controlling membrane protein activity and "raft" formation (review in Barenholz Y, Prog Lipid Res 2002, 41, 1). Do sterols & hopanoids serve the same membrane function? HO easy “flip- fl op” OH OH unkno w npro pro ppee r tie s O H OH Fig. 4. Different proportions of cholesterol and CS in GUVs modulate domain size, domain curvatures, budding, and the formation of tubular structures Bacia, KKirstenirsten et al. (2005) PProcroc . NatlNatl. AAcadcad . Sci. UUSASA 102, 3272 -3277 Courtesy of National Academy of Sciences, U. S. A. Used with permission. Source: Bacia, Kirsten et al. (2005) National Academy of Sciences, USA 102, 3272-3277. Copyright (c) 2005, National Academy of Sciences, U.S.A.�� Copyright ©2005 by the National Academy of Sciences Fig.
    [Show full text]